In a stunning revelation, Tom Homan, Trump's former border czar, was recorded accepting $50,000 in an undercover FBI sting. The investigation raises serious questions about political favoritism and corruption.
The assassination of conservative influencer Charlie Kirk has left the social media landscape reeling, forcing creators to reassess their safety and the dynamics of audience interaction.
Christine Lagarde, head of the ECB, warns that undermining the Federal Reserve's independence by President Trump could lead to severe global economic consequences. Discover the implications and ongoing tensions!
Jim O’Neill steps in as acting CDC director, replacing Susan Monarez amid controversy over vaccine policies. With ties to RFK Jr. and a libertarian stance, will he advocate for public health or follow orders?
In a bold move, President Trump seeks to fire Fed Governor Lisa Cook over unproven mortgage fraud allegations, raising questions about his influence on the central bank and the economy.
In a controversial 5-4 ruling, the Supreme Court temporarily halted $783 million in NIH research grants, igniting debates over the Trump administration's funding cuts and the implications for scientific research.
President Trump has announced plans to audit the Smithsonian and other museums, aiming to eliminate 'woke' influences. Critics warn this could threaten historical representation and independence in American cultural institutions.
Rep. Cherrish Pryor warns that the contentious Texas redistricting could soon affect Indiana. With Trump urging redraws and Democrats strategizing from afar, the political landscape is shifting rapidly. Can Indiana escape the fallout?
President Trump has nominated conservative economist E.J. Antoni to lead the Bureau of Labor Statistics, just days after firing the previous chief over disappointing job reports. Will this move ensure honest economic data?
Dr. Vinay Prasad is back at the FDA's Center for Biologics Evaluation and Research, raising eyebrows after being ousted amid political turmoil and criticism. His return ignites debates about drug approvals and public health leadership under the Trump administration.
